Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
WAVE Life Sciences (WVE) PT Lowered to $6 at Stifel
May 14, 2021 8:47 AM EDTStifel analyst Paul Matteis lowered the price target on WAVE Life Sciences (NASDAQ: WVE) to $6.00 (from $7.00) while maintaining a Hold rating.
The analyst commented, "We are reiterating our Hold rating on Wave after a 1Q21 print that was punctuated by the... More
WAVE Life Sciences (WVE) Misses Q1 EPS by 27c
May 13, 2021 7:34 AM EDTWAVE Life Sciences (NASDAQ: WVE) reported Q1 EPS of ($0.86), $0.27 worse than the analyst estimate of ($0.59).
Despite our PRECISION-HD results at the end of the first quarter, it has been a productive start of the year for Wave and our team remains focused on advancing our clinical trials for... More
